{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:44:36Z","timestamp":1770511476720,"version":"3.49.0"},"reference-count":10,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":603,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1111\/bjh.12711","type":"journal-article","created":{"date-parts":[[2014,1,6]],"date-time":"2014-01-06T09:26:48Z","timestamp":1389000408000},"page":"151-153","source":"Crossref","is-referenced-by-count":8,"title":["Milatuzumab and veltuzumab induce apoptosis through JNK signalling in an NF-\u03baB dependent human transformed follicular lymphoma cell line"],"prefix":"10.1111","volume":"165","author":[{"given":"Mitchell R.","family":"Smith","sequence":"first","affiliation":[{"name":"Taussig Cancer Institute; Cleveland Clinic; Cleveland OH USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology; Fox Chase Cancer Center; Philadelphia PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indira","family":"Joshi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology; Fox Chase Cancer Center; Philadelphia PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,1,6]]},"reference":[{"key":"10.1111\/bjh.12711-BIB0001|bjh12711-cit-0001","doi-asserted-by":"crossref","first-page":"6245","DOI":"10.1038\/onc.2008.301","article-title":"JNK signaling in apoptosis","volume":"27","author":"Dhanasekaran","year":"2008","journal-title":"Oncogene"},{"key":"10.1111\/bjh.12711-BIB0002|bjh12711-cit-0002","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2008-07-168146","article-title":"Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody","volume":"113","author":"Goldenberg","year":"2009","journal-title":"Blood"},{"key":"10.1111\/bjh.12711-BIB0003|bjh12711-cit-0003","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/blood-2006-07-025809","article-title":"Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications","volume":"109","author":"Jost","year":"2007","journal-title":"Blood"},{"key":"10.1111\/bjh.12711-BIB0004|bjh12711-cit-0004","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1158\/1078-0432.28.11.1","article-title":"Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling","volume":"11","author":"Lam","year":"2005","journal-title":"Clinical Cancer Research"},{"key":"10.1111\/bjh.12711-BIB0005|bjh12711-cit-0005","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1038\/sj.onc.1210370","article-title":"Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies","volume":"26","author":"Leonard","year":"2007","journal-title":"Oncogene"},{"key":"10.1111\/bjh.12711-BIB0006|bjh12711-cit-0006","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0165-4608(93)90132-6","article-title":"A unique EBV-negative low-grade lymphoma line (WSU-FSCCL) exhibiting both t(14;18) and t(8;11)","volume":"70","author":"Mohammad","year":"1993","journal-title":"Cancer Genetics and Cytogenetics"},{"key":"10.1111\/bjh.12711-BIB0007|bjh12711-cit-0007","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1158\/1535-7163.1693.3.12","article-title":"Enhanced efficacy of therapy with antisense bcl-2 oligonucleotides+anti-CD20 monoclonal antibody in scid mouse\/human lymphoma xenografts","volume":"3","author":"Smith","year":"2004","journal-title":"Molecular Cancer Therapy"},{"key":"10.1111\/bjh.12711-BIB0008|bjh12711-cit-0008","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1471-2407-5-103","article-title":"Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20\u00a0+\u00a0 non-Hodgkin's lymphoma cell lines in vitro and in scid mice","volume":"5","author":"Smith","year":"2005","journal-title":"BMC Cancer"},{"key":"10.1111\/bjh.12711-BIB0009|bjh12711-cit-0009","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/leu.2012.370","article-title":"Murine mantle cell lymphoma model cell line","volume":"27","author":"Smith","year":"2013","journal-title":"Leukemia"},{"key":"10.1111\/bjh.12711-BIB0010|bjh12711-cit-0010","doi-asserted-by":"crossref","first-page":"5556s","DOI":"10.1158\/1078-0432.CCR-07-1167","article-title":"CD74: a new candidate target for the immunotherapy of B-cell neoplasms","volume":"13","author":"Stein","year":"2007","journal-title":"Clinical Cancer Research"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12711","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjh.12711\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T13:13:53Z","timestamp":1688908433000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,6]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,4]]}},"URL":"https:\/\/doi.org\/10.1111\/bjh.12711","relation":{},"ISSN":["0007-1048"],"issn-type":[{"value":"0007-1048","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1,6]]}}}